DementiaVR&DementiaNCT06923358
Virtual Nature as a Health-promoting Intervention for Nursing Home Residents With Dementia
A study testing Virtual Nature intervention (VN) in people with Dementia and Nursing Home Resident, run by University of South-Eastern Norway at 1 site in Norway.
Trial summary
Rationale and Objectives: Despite significant efforts from healthcare professionals, nursing home residents with dementia often face isolation and a reduced quality of life. Increasing attention has been given to digital solutions as a complement to pharmaceutical treatments. Read more about this study
- Who is it for?
- Any age
- Conditions the study is for
- Dementia, Nursing Home Resident, Virtual Reality
- What is being tested?
- Virtual Nature intervention (VN)
- Could I receive a placebo?
- No, everyone receives an active treatment
- How many people
- 60 participants
- Where
- 1 siteNorway
- Study dates
- 8 Sep 2025to Dec 2026
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages Any age
- All sexes
- No healthy volunteers
- Child, Adult, Older adult
Who may be able to join
- Nursing-home resident
- Dementia or pre-dementia
Who cannot join
- Sub-normal sight even when corrected
- Unable to communicate in Norwegian
- Reported or exhibited high intolerance to VN exposure
Trial locations and contacts
1 site in 1 country.
About this study
Official title: Virtual Nature as a Health-promoting Intervention for Nursing Home Residents With Dementia - a Randomized Controlled Trial
Rationale and Objectives:
Despite significant efforts from healthcare professionals, nursing home residents with dementia often face isolation and a reduced quality of life. Increasing attention has been given to digital solutions as a complement to pharmaceutical treatments. In particular, Virtual Nature (VN; i.e., virtual reality simulations that simulate nature experiences) has emerged as a promising, cost-effective approach to enhancing quality of life and slowing cognitive decline in nursing home residents with dementia. This project aims to assess the long-term effects of a VN intervention on various health and well-being indicators in nursing home residents with dementia.
Read more
Design:
The study will be conducted as a randomized controlled trial with parallel conditions. Participants will be randomly assigned to either a treatment or a control group. The treatment group will undergo a 12-week VN intervention in addition to usual medications and nursing home activities, while the control group will continue with their usual medications and activities. Assessments will be performed at baseline, in concomitance with the first VN session, and at 4 and 12 weeks into the intervention.
VN intervention:
The intervention will consist of undergoing a 10-minute VN session twice a week for 12 consecutive weeks. The participants will choose a 360° video from a library of different VN scenarios. The 360° videos within the library will be filmed by the researchers in locations near or in the same region of the participant's nursing homes, and will consist of scenes from various seasons in Norway (spring, summer, fall, winter) and depict popular outdoor recreations such as hiking and cross-country skiing. The VN sessions will be delivered in the participants' room. The playback will be done through a Meta Quest 3 (Reality Labs
, USA). The intervention will be delivered by the researchers in collaboration with caregivers and/or nursing students in practice.
Participants:
Sixty nursing home residents with dementia will be recruited from different nursing homes in Drammen municipality and randomly assigned to the treatment or the control condition. The treatment group will undergo the VN intervention while continuing to receive their usual medications and attending regular activities at their respective nursing homes. The control group will only continue receiving their usual medication and attending regular activities at their respective nursing homes. Inclusion criteria are: being a nursing-home resident with a dementia diagnosis, having normal or corrected-to-normal sight and being able to communicate in Norwegian. Additionally, participants will be excluded if deemed to have poor tolerance to the VN experience (this will be evaluated based on preliminary trials and discussions with caregivers). Written informed consent will be collected for all participants (either directly from the participant or, in case they are not legally competent, their caregivers), after having explained the benefits and risks of participating to them.
Instruments:
Basic demographic data (age and gender) will be recorded. To assess potential long-term effects, the following measures will be collected at baseline, week 4, and week 12 for both the treatment and control groups: Quality of Life in Late-stage Dementia scale, Cornell Scale for Depression in Dementia, Brief Agitation Rating Scale, Clinical Dementia Rating scale, and Use of psychotropic drugs.
- Conditions
- Dementia, Nursing Home Resident, Virtual Reality, Quality of Life, Mental Health
- Being tested
- Virtual Nature intervention (VN)
- Keywords
- Virtual nature
- Medical subject headings
- Dementia, Psychological Well-Being
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Virtual Nature intervention (VN)Other
The intervention will consist of a 12-week virtual nature program in which participants will engage in two sessions per week. During each session, they will watch a 10-minute 360° video depicting a natural setting. Participants will select videos from a curated library of nature scenarios filmed by researchers in locations near or within the same region as their nursing homes. The videos will showcase various seasons in Norway (spring, summer, fall, and winter) and include popular activities such as hiking and cross-country skiing. The videos will be played using a Meta Quest 3 headset, with sessions conducted in participants' rooms by nursing home staff-except for the first session, which will be facilitated by the researchers.
| Study group | Role | What they receive |
|---|---|---|
| Virtual Nature intervention (VN) | Experimental | A 12-week virtual nature (VN) intervention, alongside regular medications and nursing home activities. Receives: Other: Virtual Nature intervention (VN) |
| Control (TAU) | No intervention | Only the regular medications and nursing home activities ("treatment as usual") |
What is being measured
The primary outcome is the main question the study is designed to answer.
Quality of Life in Late-stage Dementia scale
The Quality of Life in Late-Stage Dementia (QUALID) scale is an observational tool used to assess quality of life in individuals with advanced dementia. It consists of 11 items that evaluate various aspects of well-being, including physical comfort, social interaction, and emotional state. The scale is completed by caregivers or healthcare professionals based on their observations of the individual's behavior and condition. Each item is rated on a 5-point scale, resulting in a total score ranging from 11 to 55, where lower scores indicate better quality of life. The QUALID scale is widely used to assess the impact of interventions and care strategies, helping to ensure comfort and dignity in the final stages of life.
Measured: Before the intervention (baseline)
Quality of Life in Late-stage Dementia scale
The Quality of Life in Late-Stage Dementia (QUALID) scale is an observational tool used to assess quality of life in individuals with advanced dementia. It consists of 11 items that evaluate various aspects of well-being, including physical comfort, social interaction, and emotional state. The scale is completed by caregivers or healthcare professionals based on their observations of the individual's behavior and condition. Each item is rated on a 5-point scale, resulting in a total score ranging from 11 to 55, where lower scores indicate better quality of life. The QUALID scale is widely used to assess the impact of interventions and care strategies, helping to ensure comfort and dignity in the final stages of life.
Measured: During the intervention (4 weeks)
Quality of Life in Late-stage Dementia scale
The Quality of Life in Late-Stage Dementia (QUALID) scale is an observational tool used to assess quality of life in individuals with advanced dementia. It consists of 11 items that evaluate various aspects of well-being, including physical comfort, social interaction, and emotional state. The scale is completed by caregivers or healthcare professionals based on their observations of the individual's behavior and condition. Each item is rated on a 5-point scale, resulting in a total score ranging from 11 to 55, where lower scores indicate better quality of life. The QUALID scale is widely used to assess the impact of interventions and care strategies, helping to ensure comfort and dignity in the final stages of life.
Measured: Immediately after the intervention (12 weeks)
Secondary outcomes (12)
Cornell Scale for Depression in Dementia
The Cornell Scale for Depression in Dementia (CSDD) is a clinician-administered assessment tool developed to evaluate depressive symptoms in individuals with dementia. It combines information from direct interviews with the patient and observations reported by caregivers, allowing for the detection of mood-related symptoms that may not be reliably self-reported due to cognitive impairment. The scale includes 19 items across domains such as mood, behavior, physical signs, and circadian functions. Each item is rated on a 3-point scale (0 = absent, 1 = mild or intermittent, 2 = severe), resulting in a total score ranging from 0 to 38, where higher scores indicate more severe depressive symptoms. The CSDD is commonly used in both clinical and research contexts to identify and monitor depression in individuals with dementia.
Measured: Before the intervention (baseline)
Cornell Scale for Depression in Dementia
The Cornell Scale for Depression in Dementia (CSDD) is a clinician-administered assessment tool developed to evaluate depressive symptoms in individuals with dementia. It combines information from direct interviews with the patient and observations reported by caregivers, allowing for the detection of mood-related symptoms that may not be reliably self-reported due to cognitive impairment. The scale includes 19 items across domains such as mood, behavior, physical signs, and circadian functions. Each item is rated on a 3-point scale (0 = absent, 1 = mild or intermittent, 2 = severe), resulting in a total score ranging from 0 to 38, where higher scores indicate more severe depressive symptoms. The CSDD is commonly used in both clinical and research contexts to identify and monitor depression in individuals with dementia.
Measured: During the intervention (4 weeks)
Cornell Scale for Depression in Dementia
The Cornell Scale for Depression in Dementia (CSDD) is a clinician-administered assessment tool developed to evaluate depressive symptoms in individuals with dementia. It combines information from direct interviews with the patient and observations reported by caregivers, allowing for the detection of mood-related symptoms that may not be reliably self-reported due to cognitive impairment. The scale includes 19 items across domains such as mood, behavior, physical signs, and circadian functions. Each item is rated on a 3-point scale (0 = absent, 1 = mild or intermittent, 2 = severe), resulting in a total score ranging from 0 to 38, where higher scores indicate more severe depressive symptoms. The CSDD is commonly used in both clinical and research contexts to identify and monitor depression in individuals with dementia.
Measured: Immediately after the intervention (12 weeks)
Brief Agitation Rating Scale
The Brief Agitation Rating Scale (BARS) is an observational assessment tool developed to measure the severity of agitation in individuals with cognitive impairments, including dementia. The scale includes 10 items that evaluate behaviors such as restlessness, irritability, verbal aggression, and physical aggression. Each item is rated on a 4-point scale (0 = not present, 1 = mild, 2 = moderate, 3 = severe), resulting in a total score ranging from 0 to 30, where higher scores indicate more severe agitation. The BARS is designed to be brief and practical, enabling quick assessment by caregivers or clinicians in both clinical and research settings.
Measured: Before the intervention (baseline)
Brief Agitation Rating Scale
The Brief Agitation Rating Scale (BARS) is an observational assessment tool developed to measure the severity of agitation in individuals with cognitive impairments, including dementia. The scale includes 10 items that evaluate behaviors such as restlessness, irritability, verbal aggression, and physical aggression. Each item is rated on a 4-point scale (0 = not present, 1 = mild, 2 = moderate, 3 = severe), resulting in a total score ranging from 0 to 30, where higher scores indicate more severe agitation. The BARS is designed to be brief and practical, enabling quick assessment by caregivers or clinicians in both clinical and research settings.
Measured: During the intervention (4 weeks)
Brief Agitation Rating Scale
The Brief Agitation Rating Scale (BARS) is an observational assessment tool developed to measure the severity of agitation in individuals with cognitive impairments, including dementia. The scale includes 10 items that evaluate behaviors such as restlessness, irritability, verbal aggression, and physical aggression. Each item is rated on a 4-point scale (0 = not present, 1 = mild, 2 = moderate, 3 = severe), resulting in a total score ranging from 0 to 30, where higher scores indicate more severe agitation. The BARS is designed to be brief and practical, enabling quick assessment by caregivers or clinicians in both clinical and research settings.
Measured: Immediately after the intervention (12 weeks)
Clinical Dementia Rating scale
The Clinical Dementia Rating (CDR) scale is a widely used clinical tool for assessing the severity of dementia by evaluating both cognitive and functional decline. It examines six domains: memory, orientation, judgment and problem-solving, community affairs, home and hobbies, and personal care. Each domain is scored on a 5-point scale, ranging from "no impairment" to "severe impairment". The total CDR score (0, 0.5, 1, 2, or 3) reflects the overall stage of dementia, where higher scores indicate more severe impairment.
Measured: Before the intervention (baseline)
Clinical Dementia Rating scale
The Clinical Dementia Rating (CDR) scale is a widely used clinical tool for assessing the severity of dementia by evaluating both cognitive and functional decline. It examines six domains: memory, orientation, judgment and problem-solving, community affairs, home and hobbies, and personal care. Each domain is scored on a 5-point scale, ranging from "no impairment" to "severe impairment". The total CDR score (0, 0.5, 1, 2, or 3) reflects the overall stage of dementia, where higher scores indicate more severe impairment.
Measured: During the intervention (4 weeks)
Clinical Dementia Rating scale
The Clinical Dementia Rating (CDR) scale is a widely used clinical tool for assessing the severity of dementia by evaluating both cognitive and functional decline. It examines six domains: memory, orientation, judgment and problem-solving, community affairs, home and hobbies, and personal care. Each domain is scored on a 5-point scale, ranging from "no impairment" to "severe impairment". The total CDR score (0, 0.5, 1, 2, or 3) reflects the overall stage of dementia, where higher scores indicate more severe impairment.
Measured: Immediately after the intervention (12 weeks)
Use of psychotropic drugs
Use of psychotropic drugs, as reported by nursing staff, including medications for mood disorders, anxiety, depression, and sleep disturbances, are commonly prescribed to manage symptoms in dementia patients. Nursing staff are asked to provide detailed information on the types, dosages, and frequency of psychotropic drugs administered to residents throughout the study period. This measure will help evaluate potential changes in medication usage related to the virtual nature intervention, providing insight into its effects on behavioral and psychological symptoms of dementia.
Measured: Before the intervention (baseline)
Use of psychotropic drugs
Use of psychotropic drugs, as reported by nursing staff, including medications for mood disorders, anxiety, depression, and sleep disturbances, are commonly prescribed to manage symptoms in dementia patients. Nursing staff are asked to provide detailed information on the types, dosages, and frequency of psychotropic drugs administered to residents throughout the study period. This measure will help evaluate potential changes in medication usage related to the virtual nature intervention, providing insight into its effects on behavioral and psychological symptoms of dementia.
Measured: During the intervention (4 weeks)
Use of psychotropic drugs
Use of psychotropic drugs, as reported by nursing staff, including medications for mood disorders, anxiety, depression, and sleep disturbances, are commonly prescribed to manage symptoms in dementia patients. Nursing staff are asked to provide detailed information on the types, dosages, and frequency of psychotropic drugs administered to residents throughout the study period. This measure will help evaluate potential changes in medication usage related to the virtual nature intervention, providing insight into its effects on behavioral and psychological symptoms of dementia.
Measured: Immediately after the intervention (12 weeks)
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted11 Apr 2025
- Study start8 Sep 2025
- Primary completionDec 2026 (estimated)
- Study completionDec 2026 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Publications (4)Papers the sponsor has linked to this study.
- Other trials for DementiaStudies of the same condition, open and under way.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of South-Eastern Norway
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Giovanna Calogiuri, University of South-Eastern Norway
- Investigators
- Giovanna Calogiuri, Principal investigator, University of South-Eastern Norway
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06923358
- Sponsor's protocol ID
- 819127
- Acronym
- VR&Dementia
- Status last verified
- Apr 2026
- First submitted
- 6 Mar 2025
- Last updated
- 24 Apr 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Publications
Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993 Nov;43(11):2412-4. doi: 10.1212/wnl.43.11.2412-a. No abstract available.
PubMed 8232972Finkel SI, Lyons JS, Anderson RL. A brief agitation rating scale (BARS) for nursing home elderly. J Am Geriatr Soc. 1993 Jan;41(1):50-2. doi: 10.1111/j.1532-5415.1993.tb05948.x.
PubMed 8418123Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. Biol Psychiatry. 1988 Feb 1;23(3):271-84. doi: 10.1016/0006-3223(88)90038-8.
PubMed 3337862Roen I, Selbaek G, Kirkevold O, Engedal K, Lerdal A, Bergh S. The Reliability and Validity of the Norwegian Version of the Quality of Life in Late-Stage Dementia Scale. Dement Geriatr Cogn Disord. 2015;40(3-4):233-42. doi: 10.1159/000437093. Epub 2015 Jul 28.
PubMed 26227299
Study at a glance
From the registry record, last updated by the sponsor on 24 Apr 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Virtual Nature as a Health-promoting Intervention for Nursing Home Residents With Dementia - a Randomized Controlled Trial
- ClinicalTrials.gov ID
- NCT06923358
- Acronym / sponsor ID
- VR&Dementia / 819127
- Conditions
- Dementia, Nursing Home Resident, Virtual Reality, Quality of Life, Mental Health
- Keywords
- Virtual nature
- Study type
- Interventional
- Recruitment status
- Active, not recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- University of South-Eastern NorwayUniversity, hospital or other
- Study start
- 8 Sep 2025 (actual)
- Primary completion
- Dec 2026 (estimated)
- Study completion
- Dec 2026 (estimated)
- First posted
- 11 Apr 2025 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
Rationale and Objectives:
Despite significant efforts from healthcare professionals, nursing home residents with dementia often face isolation and a reduced quality of life. Increasing attention has been given to digital solutions as a complement to pharmaceutical treatments. In particular, Virtual Nature (VN; i.e., virtual reality simulations that simulate nature experiences) has emerged as a promising, cost-effective approach to enhancing quality of life and slowing cognitive decline in nursing home residents with dementia. This project aims to assess the long-term effects of a VN intervention on various health and well-being indicators in nursing home residents with dementia.
Design:
The study will be conducted as a randomized controlled trial with parallel conditions. Participants will be randomly assigned to either a treatment or a control group. The treatment group will undergo a 12-week VN intervention in addition to usual medications and nursing home activities, while the control group will continue with their usual medications and activities. Assessments will be performed at baseline, in concomitance with the first VN session, and at 4 and 12 weeks into the intervention.
VN intervention:
The intervention will consist of undergoing a 10-minute VN session twice a week for 12 consecutive weeks. The participants will choose a 360° video from a library of different VN scenarios. The 360° videos within the library will be filmed by the researchers in locations near or in the same region of the participant's nursing homes, and will consist of scenes from various seasons in Norway (spring, summer, fall, winter) and depict popular outdoor recreations such as hiking and cross-country skiing. The VN sessions will be delivered in the participants' room. The playback will be done through a Meta Quest 3 (Reality Labs
, USA). The intervention will be delivered by the researchers in collaboration with caregivers and/or nursing students in practice.
Participants:
Sixty nursing home residents with dementia will be recruited from different nursing homes in Drammen municipality and randomly assigned to the treatment or the control condition. The treatment group will undergo the VN intervention while continuing to receive their usual medications and attending regular activities at their respective nursing homes. The control group will only continue receiving their usual medication and attending regular activities at their respective nursing homes. Inclusion criteria are: being a nursing-home resident with a dementia diagnosis, having normal or corrected-to-normal sight and being able to communicate in Norwegian. Additionally, participants will be excluded if deemed to have poor tolerance to the VN experience (this will be evaluated based on preliminary trials and discussions with caregivers). Written informed consent will be collected for all participants (either directly from the participant or, in case they are not legally competent, their caregivers), after having explained the benefits and risks of participating to them.
Instruments:
Basic demographic data (age and gender) will be recorded. To assess potential long-term effects, the following measures will be collected at baseline, week 4, and week 12 for both the treatment and control groups: Quality of Life in Late-stage Dementia scale, Cornell Scale for Depression in Dementia, Brief Agitation Rating Scale, Clinical Dementia Rating scale, and Use of psychotropic drugs.
Study design
- Primary purpose
- Supportive care
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- None (open label)
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Virtual Nature intervention (VN) | Experimental | Other: Virtual Nature intervention (VN)A 12-week virtual nature (VN) intervention, alongside regular medications and nursing home activities. |
| Control (TAU) | No intervention | –Only the regular medications and nursing home activities ("treatment as usual") |
Who may qualify
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (2 listed)
- Nursing-home resident
- Dementia or pre-dementia
Key exclusion criteria (3 listed)
- Sub-normal sight even when corrected
- Unable to communicate in Norwegian
- Reported or exhibited high intolerance to VN exposure
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Virtual Nature intervention (VN)The intervention will consist of a 12-week virtual nature program in which participants will engage in two sessions per week. During each session, they will watch a 10-minute 360° video depicting a natural setting. Participants will select videos from a curated library of nature scenarios filmed by researchers in locations near or within the same region as their nursing homes. The videos will showcase various seasons in Norway (spring, summer, fall, and winter) and include popular activities such as hiking and cross-country skiing. The videos will be played using a Meta Quest 3 headset, with sessions conducted in participants' rooms by nursing home staff-except for the first session, which will be facilitated by the researchers. | Other | Virtual Nature intervention (VN) |
Primary outcome
Quality of Life in Late-stage Dementia scale
Time frame: Before the intervention (baseline)
The Quality of Life in Late-Stage Dementia (QUALID) scale is an observational tool used to assess quality of life in individuals with advanced dementia. It consists of 11 items that evaluate various aspects of well-being, including physical comfort, social interaction, and emotional state. The scale is completed by caregivers or healthcare professionals based on their observations of the individual's behavior and condition. Each item is rated on a 5-point scale, resulting in a total score ranging from 11 to 55, where lower scores indicate better quality of life. The QUALID scale is widely used to assess the impact of interventions and care strategies, helping to ensure comfort and dignity in the final stages of life.
Quality of Life in Late-stage Dementia scale
Time frame: During the intervention (4 weeks)
The Quality of Life in Late-Stage Dementia (QUALID) scale is an observational tool used to assess quality of life in individuals with advanced dementia. It consists of 11 items that evaluate various aspects of well-being, including physical comfort, social interaction, and emotional state. The scale is completed by caregivers or healthcare professionals based on their observations of the individual's behavior and condition. Each item is rated on a 5-point scale, resulting in a total score ranging from 11 to 55, where lower scores indicate better quality of life. The QUALID scale is widely used to assess the impact of interventions and care strategies, helping to ensure comfort and dignity in the final stages of life.
Quality of Life in Late-stage Dementia scale
Time frame: Immediately after the intervention (12 weeks)
The Quality of Life in Late-Stage Dementia (QUALID) scale is an observational tool used to assess quality of life in individuals with advanced dementia. It consists of 11 items that evaluate various aspects of well-being, including physical comfort, social interaction, and emotional state. The scale is completed by caregivers or healthcare professionals based on their observations of the individual's behavior and condition. Each item is rated on a 5-point scale, resulting in a total score ranging from 11 to 55, where lower scores indicate better quality of life. The QUALID scale is widely used to assess the impact of interventions and care strategies, helping to ensure comfort and dignity in the final stages of life.
12 secondary outcomes
Cornell Scale for Depression in Dementia
Time frame: Before the intervention (baseline)
Cornell Scale for Depression in Dementia
Time frame: During the intervention (4 weeks)
Cornell Scale for Depression in Dementia
Time frame: Immediately after the intervention (12 weeks)
Brief Agitation Rating Scale
Time frame: Before the intervention (baseline)
Brief Agitation Rating Scale
Time frame: During the intervention (4 weeks)
Brief Agitation Rating Scale
Time frame: Immediately after the intervention (12 weeks)
Clinical Dementia Rating scale
Time frame: Before the intervention (baseline)
Clinical Dementia Rating scale
Time frame: During the intervention (4 weeks)
Clinical Dementia Rating scale
Time frame: Immediately after the intervention (12 weeks)
Use of psychotropic drugs
Time frame: Before the intervention (baseline)
Use of psychotropic drugs
Time frame: During the intervention (4 weeks)
Use of psychotropic drugs
Time frame: Immediately after the intervention (12 weeks)
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 24 Apr 2026.
- Background: PubMed 8232972Morris JC. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology. 1993 Nov;43(11):2412-4. doi: 10.1212/wnl.43.11.2412-a. No abstract available.
- Background: PubMed 8418123Finkel SI, Lyons JS, Anderson RL. A brief agitation rating scale (BARS) for nursing home elderly. J Am Geriatr Soc. 1993 Jan;41(1):50-2. doi: 10.1111/j.1532-5415.1993.tb05948.x.
- Background: PubMed 3337862Alexopoulos GS, Abrams RC, Young RC, Shamoian CA. Cornell Scale for Depression in Dementia. Biol Psychiatry. 1988 Feb 1;23(3):271-84. doi: 10.1016/0006-3223(88)90038-8.
- Background: PubMed 26227299Roen I, Selbaek G, Kirkevold O, Engedal K, Lerdal A, Bergh S. The Reliability and Validity of the Norwegian Version of the Quality of Life in Late-Stage Dementia Scale. Dement Geriatr Cogn Disord. 2015;40(3-4):233-42. doi: 10.1159/000437093. Epub 2015 Jul 28.
- Poster presented at the Norwegian Public Health conference, October 24-25, 2024, Tønsberg, NorwayLink provided by the sponsor.
Related trials for Dementia
RecruitingPhase 2
Neuroplasticity Enhancement From Cognitive Training Reinforced by Psilocybin
Alzheimer's Disease
Not yet recruiting
Acupressure as Long-term Intervention to Slow the Progression of Early/Mild Alzheimer's Disease
Alzheimer's Disease
RecruitingObservational study
Effectiveness and Safety of Disease-Modifying Therapy for Alzheimer's Disease: A Multicenter Retrospective Study
Alzheimer's Disease (AD)
Not yet recruitingPhase 2
Lisdexamfetamine For the Treatment of Conduct Disorder in Children
Conduct Disorder
RecruitingPhase 3
A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitation Associated With Alzheimer's Disease (ADAGIO-1)
Alzheimer Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.
Giovanna Calogiuri principal investigator
University of South-Eastern Norway
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Virtual Nature intervention (VN) in people with Dementia and Nursing Home Resident, run by University of South-Eastern Norway at 1 site in Norway.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 2 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: under way, not looking for participants, as of the sponsor's last update on 24 Apr 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Norway. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Quality of Life in Late-stage Dementia scale (time frame: Before the intervention (baseline)). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
On the ClinicalTrials.gov record for NCT06923358, which also lists 4 linked publications.
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 24 Apr 2026.